These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34762647)

  • 21. Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA
    Liu XL; Liu JL; Xu YC; Zhang X; Wang YX; Qing LH; Guo W; Ding J; Meng LH
    Int J Cancer; 2019 Aug; 145(3):817-829. PubMed ID: 30671946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
    Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
    Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
    Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NODAL/TGFβ signalling mediates the self-sustained stemness induced by PIK3CAH1047R homozygosity in pluripotent stem cells.
    Madsen RR; Longden J; Knox RG; Robin X; Völlmy F; Macleod KG; Moniz LS; Carragher NO; Linding R; Vanhaesebroeck B; Semple RK
    Dis Model Mech; 2021 Mar; 14(3):. PubMed ID: 33514588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.
    Zheng S; He S; Liang Y; Tan Y; Liu Q; Liu T; Lu X
    Mol Biomed; 2024 Apr; 5(1):13. PubMed ID: 38616230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
    Janku F; Tsimberidou AM; Garrido-Laguna I; Wang X; Luthra R; Hong DS; Naing A; Falchook GS; Moroney JW; Piha-Paul SA; Wheler JJ; Moulder SL; Fu S; Kurzrock R
    Mol Cancer Ther; 2011 Mar; 10(3):558-65. PubMed ID: 21216929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer-A Preliminary Study.
    Kołodziej P; Nicoś M; Krawczyk PA; Bogucki J; Karczmarczyk A; Zalewski D; Kubrak T; Kołodziej E; Makuch-Kocka A; Madej-Czerwonka B; Płachno BJ; Kocki J; Bogucka-Kocka A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
    Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
    Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and functional characterization of germline PIK3CA variants in patients with PIK3CA-related overgrowth spectrum disorders.
    Cooley Coleman JA; Gass JM; Srikanth S; Pauly R; Ziats CA; Everman DB; Skinner SA; Bell S; Louie RJ; Cascio L; Patterson WG; Jones JR; Di Donato N; Stevenson RE; Boccuto L
    Hum Mol Genet; 2023 Apr; 32(9):1457-1465. PubMed ID: 36458889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
    Loi S; Michiels S; Baselga J; Bartlett JM; Singhal SK; Sabine VS; Sims AH; Sahmoud T; Dixon JM; Piccart MJ; Sotiriou C
    PLoS One; 2013; 8(1):e53292. PubMed ID: 23301057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
    Ciruelos Gil EM
    Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
    ; ; ;
    Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
    Loi S; Haibe-Kains B; Majjaj S; Lallemand F; Durbecq V; Larsimont D; Gonzalez-Angulo AM; Pusztai L; Symmans WF; Bardelli A; Ellis P; Tutt AN; Gillett CE; Hennessy BT; Mills GB; Phillips WA; Piccart MJ; Speed TP; McArthur GA; Sotiriou C
    Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10208-13. PubMed ID: 20479250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unilateral focal palmoplantar keratoderma associated with a postzygotic variant in PIK3CA and activation of the PI3K/AKT/mTOR pathway.
    Gong Z; Peng S; Wang H; Jiang X; Ke X; Lin Z
    Eur J Dermatol; 2024 Jun; 34(3):287-293. PubMed ID: 39015962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.